QUICK SEARCH:   [advanced] Author: Keyword(s):
Home     Help     Feedback     Subscriptions     Archive     Search     Table of Contents

First published online 20 January 2004
doi: 10.1242/jcs.00898

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: jcs.00898v1 117/5/677    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by De la Vieja, A. Articles by Carrasco, N. Search for Related Content PubMed PubMed Citation Articles by De la Vieja, A. Articles by Carrasco, N.

The Q267E mutation in the sodium/iodide symporter (NIS) causes congenital iodide transport defect (ITD) by decreasing the NIS turnover number

Department of Molecular Pharmacology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA

^* Author for correspondence (e-mail: carrasco{at}aecom.yu.edu)

Accepted 19 September 2003

The Na⁺/I^- symporter (NIS) is a key plasma membrane glycoprotein that mediates active iodide (I^-) transport in the thyroid and other tissues. Since isolation of the cDNA encoding NIS (G. Dai, O. Levy, and N. Carrasco (1996) Nature 379, 458-460), ten mutations in NIS have been identified as causes of congenital iodide transport defect (ITD). Two of these mutations (T354P and G395R) have been thoroughly characterized at the molecular level. Both mutant NIS proteins are inactive but normally expressed and correctly targeted to the plasma membrane. The hydroxyl group at the ß-carbon of residue 354 is essential for NIS function, whereas the presence of a charged or large side-chain at position 395 interferes with NIS function. We report the extensive molecular analysis of the Q267E mutation in COS-7 cells transfected with rat or human Q267E NIS cDNA constructs. We used site-directed mutagenesis to engineer various residue substitutions into position 267. In contrast to previous suggestions that Q267E NIS was inactive, possibly because of a trafficking defect, we conclusively show that Q267E NIS is modestly active and properly targeted to the plasma membrane. Q267E NIS exhibited lower V_max values for I^- than wild-type NIS, suggesting that the decreased level of activity of Q267E NIS is due to a lower catalytic rate. That Q267E NIS retains even partial activity sets this ITD-causing mutant apart from T354P and G395R NIS. The presence of charged residues (of any polarity) other than Glu at position 267 rendered NIS inactive without affecting its expression or targeting, but substitution with neutral residues at this position was compatible with partial activity.

Key words: NIS (sodium/iodide symporter), ITD (iodide transport defect), Thyroid, Membrane proteins

This article has been cited by other articles:

				M. D. Reed-Tsur, A. De la Vieja, C. S. Ginter, and N. Carrasco Molecular Characterization of V59E NIS, a Na+/I- Symporter Mutant that Causes Congenital I- Transport Defect Endocrinology, June 1, 2008; 149(6): 3077 - 3084. [Abstract] [Full Text] [PDF]

				M. Dayem, C. Basquin, V. Navarro, P. Carrier, R. Marsault, P. Chang, S. Huc, E. Darrouzet, S. Lindenthal, and T. Pourcher Comparison of expressed human and mouse sodium/iodide symporters reveals differences in transport properties and subcellular localization J. Endocrinol., April 1, 2008; 197(1): 95 - 109. [Abstract] [Full Text] [PDF]

				D. D. Vadysirisack, E. S.-W. Chen, Z. Zhang, M.-D. Tsai, G.-D. Chang, and S. M. Jhiang Identification of in Vivo Phosphorylation Sites and Their Functional Significance in the Sodium Iodide Symporter J. Biol. Chem., December 21, 2007; 282(51): 36820 - 36828. [Abstract] [Full Text] [PDF]

				A. De la Vieja, M. D. Reed, C. S. Ginter, and N. Carrasco Amino Acid Residues in Transmembrane Segment IX of the Na+/I Symporter Play a Role in Its Na+ Dependence and Are Critical for Transport Activity J. Biol. Chem., August 31, 2007; 282(35): 25290 - 25298. [Abstract] [Full Text] [PDF]

				G. Riesco-Eizaguirre and P. Santisteban A perspective view of sodium iodide symporter research and its clinical implications. Eur. J. Endocrinol., October 1, 2006; 155(4): 495 - 512. [Abstract] [Full Text] [PDF]

				V. Paroder, S. R. Spencer, M. Paroder, D. Arango, S. Schwartz Jr., J. M. Mariadason, L. H. Augenlicht, S. Eskandari, and N. Carrasco Na+/monocarboxylate transport (SMCT) protein expression correlates with survival in colon cancer: Molecular characterization of SMCT PNAS, May 9, 2006; 103(19): 7270 - 7275. [Abstract] [Full Text] [PDF]

				G. Szinnai, S. Kosugi, C. Derrien, N. Lucidarme, V. David, P. Czernichow, and M. Polak Extending the Clinical Heterogeneity of Iodide Transport Defect (ITD): A Novel Mutation R124H of the Sodium/Iodide Symporter Gene and Review of Genotype-Phenotype Correlations in ITD J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1199 - 1204. [Abstract] [Full Text] [PDF]

				A. De la Vieja, C. S. Ginter, and N. Carrasco Molecular Analysis of a Congenital Iodide Transport Defect: G543E Impairs Maturation and Trafficking of the Na+/I- Symporter Mol. Endocrinol., November 1, 2005; 19(11): 2847 - 2858. [Abstract] [Full Text] [PDF]

				Z. Zhang, Y.-Y. Liu, and S. M. Jhiang Cell Surface Targeting Accounts for the Difference in Iodide Uptake Activity between Human Na+/I- Symporter and Rat Na+/I- Symporter J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6131 - 6140. [Abstract] [Full Text] [PDF]